-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Sci-tech Innovation Board has been in the market for more than 2 years, and a relatively complete system of rules and regulations has been gradually established to help the development of "hard technology" enterprises
.
The attractiveness of the Sci-Tech Innovation Board has become stronger and stronger .
Among them, biomedical companies account for nearly one-fifth of the total number of listed companies on the Sci-tech Innovation Board
.
According to statistics, more than 28 biomedical listed companies have been listed and traded on the Sci-tech Innovation Board .
On November 17th, the IPO preparation team on the Science and Technology Innovation Board welcomed another pharmaceutical company, Baili Tianheng Pharmaceutical, whose IPO application to the Science and Technology Innovation Board has been accepted
.
Baili Tianheng Pharmaceutical Co.
, Ltd.
is a modern biopharmaceutical company integrating drug R&D, production and marketing.
The research, development and production capacity of a full range of drugs and antibody conjugate drugs (ADC drugs)
.
At present, the company has 26 key chemical drug research projects, including 20 generic drugs and 6 improved new drugs, of which 6 are in the application for listing stage and 6 are in the application for clinical and clinical trials
.
Financial data shows that in 2018, 2019, 2020, and the first half of 2021, the company achieved revenues of 1.
111 billion yuan, 1.
207 billion yuan, 1.
013 billion yuan, and 423 million yuan respectively; the corresponding net profits for the same period were 32.
828 million yuan and 774.
23 yuan respectively.
The net profit after deduction was RMB 18,214,500, RMB -38,120,700, RMB -25,04405, and RMB -32,892,700, respectively
.
However, even in the case of performance losses, Baili Tianheng still did not forget to pay dividends, and its dividends during the reporting period were 10 million, 18 million, 2 million, and 20 million
.
In addition, Baili Tianheng's accounts receivable are high, and the accounts receivable from 2018 to the first half of 2021 are 265 million yuan, 207 million yuan, 163 million yuan, and 127 million yuan respectively
.
It is worth mentioning that this is not the first time that Baili Tianheng has broken through the IPO.
The company submitted the GEM prospectus in June 2014 and December 2015, and intends to go through the GEM. .
However, due to the decline in the average price of major products and other reasons, the ChiNext IPO was terminated for review
.
The prospectus shows that Baili Tianheng Pharmaceutical chose the fourth set of criteria for the Sci-tech Innovation Board for this IPO: the estimated market value is not less than RMB 3 billion, and the operating income in the most recent year is not less than RMB 300 million
.
The company's public offering of no more than 40.
1 million ordinary shares of RMB, plans to raise 1.
422 billion yuan
.
The funds raised will be mainly used for the industrialization of antibody drugs, clinical research, and the research and development of innovative antibody drugs in the oncology and new crown fields
.
It is reported that the company will focus on biopharmaceuticals as its core business in the future
.
As early as 2011, the company began to deploy global innovative biopharmaceuticals, and was committed to the research and development of innovative macromolecular biopharmaceuticals with breakthrough curative effects and global patents and rights
.
The company uses the cash flow generated from chemical drug preparations and proprietary Chinese medicine preparations business to support and feed back the company's research and development of innovative biological drugs, so as to achieve a positive cycle of virtuous endogenous development
.
After 10 years of accumulation, the company's innovative biopharmaceutical sector has become quite large and has phased results with global competitiveness
.
As of the signing date of this prospectus, the company has 16 core innovative biopharmaceutical products under development with global rights and interests.
Among them, the bispecific antibody candidate drug SI-B001 has successively carried out 6 phase II clinical trials, and another 6 drug candidates are in I Phase of clinical research, but has not yet generated sales revenue
.
.
The attractiveness of the Sci-Tech Innovation Board has become stronger and stronger .
Among them, biomedical companies account for nearly one-fifth of the total number of listed companies on the Sci-tech Innovation Board
.
According to statistics, more than 28 biomedical listed companies have been listed and traded on the Sci-tech Innovation Board .
On November 17th, the IPO preparation team on the Science and Technology Innovation Board welcomed another pharmaceutical company, Baili Tianheng Pharmaceutical, whose IPO application to the Science and Technology Innovation Board has been accepted
.
Baili Tianheng Pharmaceutical Co.
, Ltd.
is a modern biopharmaceutical company integrating drug R&D, production and marketing.
The research, development and production capacity of a full range of drugs and antibody conjugate drugs (ADC drugs)
.
At present, the company has 26 key chemical drug research projects, including 20 generic drugs and 6 improved new drugs, of which 6 are in the application for listing stage and 6 are in the application for clinical and clinical trials
.
Financial data shows that in 2018, 2019, 2020, and the first half of 2021, the company achieved revenues of 1.
111 billion yuan, 1.
207 billion yuan, 1.
013 billion yuan, and 423 million yuan respectively; the corresponding net profits for the same period were 32.
828 million yuan and 774.
23 yuan respectively.
The net profit after deduction was RMB 18,214,500, RMB -38,120,700, RMB -25,04405, and RMB -32,892,700, respectively
.
However, even in the case of performance losses, Baili Tianheng still did not forget to pay dividends, and its dividends during the reporting period were 10 million, 18 million, 2 million, and 20 million
.
In addition, Baili Tianheng's accounts receivable are high, and the accounts receivable from 2018 to the first half of 2021 are 265 million yuan, 207 million yuan, 163 million yuan, and 127 million yuan respectively
.
It is worth mentioning that this is not the first time that Baili Tianheng has broken through the IPO.
The company submitted the GEM prospectus in June 2014 and December 2015, and intends to go through the GEM. .
However, due to the decline in the average price of major products and other reasons, the ChiNext IPO was terminated for review
.
The prospectus shows that Baili Tianheng Pharmaceutical chose the fourth set of criteria for the Sci-tech Innovation Board for this IPO: the estimated market value is not less than RMB 3 billion, and the operating income in the most recent year is not less than RMB 300 million
.
The company's public offering of no more than 40.
1 million ordinary shares of RMB, plans to raise 1.
422 billion yuan
.
The funds raised will be mainly used for the industrialization of antibody drugs, clinical research, and the research and development of innovative antibody drugs in the oncology and new crown fields
.
It is reported that the company will focus on biopharmaceuticals as its core business in the future
.
As early as 2011, the company began to deploy global innovative biopharmaceuticals, and was committed to the research and development of innovative macromolecular biopharmaceuticals with breakthrough curative effects and global patents and rights
.
The company uses the cash flow generated from chemical drug preparations and proprietary Chinese medicine preparations business to support and feed back the company's research and development of innovative biological drugs, so as to achieve a positive cycle of virtuous endogenous development
.
After 10 years of accumulation, the company's innovative biopharmaceutical sector has become quite large and has phased results with global competitiveness
.
As of the signing date of this prospectus, the company has 16 core innovative biopharmaceutical products under development with global rights and interests.
Among them, the bispecific antibody candidate drug SI-B001 has successively carried out 6 phase II clinical trials, and another 6 drug candidates are in I Phase of clinical research, but has not yet generated sales revenue
.
